RVMD has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
RVMD has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Revolution Medicines's Enterprise Value is $4,792.55 Mil. Revolution Medicines's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was $-457.88 Mil. Therefore, Revolution Medicines's EV-to-FCF for today is -10.47.
The historical rank and industry rank for Revolution Medicines's EV-to-FCF or its related term are showing as below:
During the past 7 years, the highest EV-to-FCF of Revolution Medicines was -4.17. The lowest was -35.88. And the median was -8.37.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-05-16), Revolution Medicines's stock price is $38.95. Revolution Medicines's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-3.820. Therefore, Revolution Medicines's PE Ratio for today is At Loss.
The historical data trend for Revolution Medicines's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Revolution Medicines Annual Data | ||||||||||||||||
Trend | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
EV-to-FCF | Get a 7-Day Free Trial | - | -21.64 | -8.82 | -6.69 | -8.26 |
Revolution Medicines Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
EV-to-FCF | Get a 7-Day Free Trial | -6.01 | -8.22 | -7.60 | -8.26 | -8.08 |
For the Biotechnology subindustry, Revolution Medicines's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Revolution Medicines's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Revolution Medicines's EV-to-FCF falls into.
Revolution Medicines's EV-to-FCF for today is calculated as:
EV-to-FCF | = | Enterprise Value (Today) | / | Free Cash Flow (TTM) |
= | 4792.554 | / | -457.879 | |
= | -10.47 |
Revolution Medicines's current Enterprise Value is $4,792.55 Mil.
Revolution Medicines's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-457.88 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Revolution Medicines (NAS:RVMD) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Revolution Medicines's PE Ratio for today is calculated as:
PE Ratio | = | Share Price (Today) | / | Earnings per Share (Diluted) (TTM) |
= | 38.95 | / | -3.820 | |
= | At Loss |
Revolution Medicines's share price for today is $38.95.
Revolution Medicines's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.820.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Thank you for viewing the detailed overview of Revolution Medicines's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Stephen Michael Kelsey | officer: See Remarks | C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025 |
Jeff Cislini | officer: General Counsel | C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063 |
Mark A Goldsmith | director, officer: See Remarks | 925 PAGE MILL ROAD, PALO ALTO CA 94304 |
Margaret A Horn | officer: See Remarks | 925 PAGE MILL ROAD, PALO ALTO CA 94304 |
Jack Anders | officer: Chief Financial Officer | C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063 |
Barbara Weber | director | C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063 |
Xiaolin Wang | officer: See Remarks | C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063 |
Thilo Schroeder | director | C/O NEXTECH INVEST LTD., BAHNHOFSTRASSE 18, ZURICH V8 8001 |
Lorence H. Kim | director | C/O SERES HEALTH, INC., 161 FIRST STREET, CAMBRIDGE MA 02472 |
Sushil Patel | director | C/O REPLIMUNE GROUP, INC., 500 UNICORN PARK, THIRD FLOOR, WOBURN MA 01801 |
Third Rock Ventures Iii, L.p. | 10 percent owner | 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116 |
Flavia Borellini | director | C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063 |
Third Rock Ventures Ii, L.p. | 10 percent owner | 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116 |
Peter Svennilson | director, 10 percent owner | 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
Vincent A. Miller | director | C/O FOUNDATION MEDICINE, INC., ONE KENDALL SQUARE, SUITE B3501, CAMBRIDGE MA 02139 |
From GuruFocus
By Marketwired • 08-17-2023
By Value_Insider Value_Insider • 12-07-2022
By GuruFocus Research • 10-19-2023
By sperokesalga sperokesalga • 06-08-2023
By sperokesalga sperokesalga • 05-08-2023
By sperokesalga sperokesalga • 04-13-2023
By GuruFocus Research • 09-20-2023
By Value_Insider Value_Insider • 12-19-2022
By sperokesalga sperokesalga • 03-01-2023
By Marketwired • 08-03-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.